Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment
Sonia Santander Ballestín1, María Abadía Labena2, Ana Avedillo-Salas3
1Department of Pharmacology, Phisiology, and Legal-Forensic Medicine, Faculty of Health and Sports Sciences, University of Zaragoza, 22001 Huesca, Spain.
Background And Objectives:
Breast cancer is the most common malignant neoplasm worldwide and the most prevalent one among women. It represents the leading cause of cancer-related death among females. Cyclin-dependent kinase 4 and 6 inhibitors disrupt the cell cycle, inducing cellular senescence and, ultimately, apoptosis. Consequently, they have become a novel type of adjuvant therapy for the treatment of advanced or metastatic breast cancer characterised by positive hormone receptors and human epidermal growth factor receptor 2 (HER-2) negative.
Methods:
A systematic review was conducted, analysing the available literature on cyclin-dependent kinase 4 and 6 inhibitors published over the last five years. The aim was to evaluate the efficacy and safety of adding these drugs to the standard endocrine therapy for this pathology.
Results:
The combination of cyclin-dependent kinase 4 and 6 inhibitors with endocrine therapy was shown to improve progression-free survival, overall survival, and chemotherapy-free intervals in patients who received this combination therapy.
Conclusions:
The addition of CDK4/6 inhibitors to endocrine therapy in the treatment of advanced or metastatic breast cancer with positive hormone receptors and HER-2 negative significantly improved PFS, median survival, and chemotherapy-free intervals compared with the use of hormonal treatments alone or in combination with a placebo. Currently, CDK4/6 inhibitors are becoming established as a new standard treatment for this pathology, offering lower toxicity than chemotherapy. However, it is necessary to deeply investigate the mechanisms of treatment resistance and develop effective therapies to overcome them.
Insights
Adding cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors to endocrine therapy significantly improves outcomes for advanced HER2-negative breast cancer. This novel treatment offers better survival and fewer chemotherapy-free intervals with lower toxicity.
Area of Science:
- Oncology
- Pharmacology
Background:
- Breast cancer is a leading cause of cancer death in women globally.
- Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors target cell cycle progression.
- These inhibitors are a novel adjuvant therapy for advanced or metastatic HER2-negative, hormone receptor-positive breast cancer.
Purpose of the Study:
- To evaluate the efficacy and safety of CDK4/6 inhibitors combined with standard endocrine therapy.
- To analyze recent literature on CDK4/6 inhibitors in breast cancer treatment.
Main Methods:
- Systematic review of scientific literature.
- Analysis focused on studies published within the last five years.
- Evaluation of progression-free survival, overall survival, and chemotherapy-free intervals.
Main Results:
- Combination therapy significantly improved progression-free survival (PFS).
- Overall survival and chemotherapy-free intervals were also enhanced.
- CDK4/6 inhibitors demonstrated lower toxicity compared to chemotherapy.
Conclusions:
- CDK4/6 inhibitors plus endocrine therapy are a new standard for advanced HER2-negative breast cancer.
- This combination offers improved survival benefits over hormonal therapy alone.
- Further research is needed to understand and overcome treatment resistance mechanisms.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:39Positive Regulator Molecules